News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Recursion Pharmaceuticals (RXRX) saw its stock decline by 4% after reporting Q2 2026 revenue of US$7.67 million against a net loss of US$131.01 million, highlighting significant cash burn. Despite the financial losses, the company showed progress in its AI-driven drug discovery with clinical milestones …
Recursion Pharmaceuticals (RXRX) director Blake Borgeson sold 30,000 shares of Class A Common Stock at $3.25 per share on August 4, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 31, 2025. Following the sale, Borgeson directly holds …
Recursion Pharmaceuticals (RXRX) stock has seen a significant decline over the past five years and is currently trading above its fair value based on various valuation checks. The company's P/S ratio of 30.7x is well above the biotech industry average, indicating it is expensive …
Recursion Pharmaceuticals, Inc. reported its Q2 2026 results, with revenue falling to US$7.67 million from US$19.22 million a year earlier, while its net loss narrowed to US$131.01 million and loss per share improved to US$0.25. Alongside these figures, the company highlighted progress on its …
(RTTNews) - RECURSION PHARMACEUTICALS, INC. (RXRX) released Loss for second quarter of -$131.005 million The company's earnings came in at -$131.005 million, or -$0.25 per share. This compares with -$171.897 million, or -$0.41 per share, last year. The company's revenue for the period fell …
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Recursion Pharmaceuticals stock has had a difficult run over the past several years, and the current valuation checks lean toward the shares looking …
Recursion (Nasdaq: RXRX) announced its second-quarter 2026 financial results, highlighted by Genentech advancing the first neuroscience target from their collaboration into an early discovery program. This milestone validates Recursion's AI-native platform for identifying novel biological targets. The company also provided updates on its pipeline, …
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items. This quarterly …
Salt Lake City, UT, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences: Bank of America 2026 SMID Cap Executive Insights Event — …
Salt Lake City, UT, July 31, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on July 27, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement …
Vanguard Capital Management LLC and its affiliates have disclosed a beneficial ownership of 26,744,129 shares, representing a 5.09% stake, in Recursion Pharmaceuticals Inc. (RXRX) as of June 30, 2026. This Schedule 13G filing indicates Vanguard has sole voting power over 3,978,189 shares and sole …
An insider at Recursion Pharmaceuticals, Inc. (RXRX) has filed a Rule 144 notice to sell 75,000 Class A shares through Fidelity Brokerage Services LLC, valued at approximately $225,000. These shares were acquired as Founder Shares for compensation on April 20, 2021. The filing also …
BlackRock, Inc. has filed an amended Schedule 13G disclosing an 8.5% passive ownership stake in Recursion Pharmaceuticals, Inc.'s Class A shares. This amounts to 44,541,605 shares, with BlackRock holding sole voting power over 43,812,201 shares and sole dispositive power over all 44,541,605 shares. The …
A shareholder of Recursion Pharmaceuticals, Inc. (RXRX), associated with Christopher C. Gibson, has filed a Form 144 to sell 50,000 Class A shares valued at over $151,000. These shares are identified as Founders Shares initially acquired as compensation in April 2021. The filing also …
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $2.97, marking a -2.62% move from the previous day. This move lagged the S&P 500's daily loss of 1.52%. On the other hand, the Dow registered a loss of 2.19%, and the technology-centric Nasdaq …
Sharemaestro market context Price below Trend Line 52 weeks -45.5% · Next-week setup negative 28.8%Company to host public Earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) -- Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) – Recursion (Nasdaq: RXRX), …
This article provides a revenue breakdown for Recursion Pharmaceuticals, Inc. Class A (SWB:8RL), highlighting its top-performing segment and geographical contribution. Last year, the company generated 63.22 million EUR, with the Drug Discovery segment contributing 63.58 million EUR, and the United States accounting for 33.50 …
Recursion Pharmaceuticals (RXRX) closed at $3.01 in the latest trading session, marking a +1.69% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.02%. Elsewhere, the Dow saw an upswing of 0.51%, while the tech-heavy Nasdaq depreciated by 0.18%. …
Sharemaestro market context Price below Trend Line 52 weeks -45.5% · Next-week setup negative 28.8%Christopher C. Gibson, an insider at RXRX, plans to sell 50,000 Class A shares of Recursion Pharmaceuticals (RXRX) via Fidelity Brokerage Services LLC on NASDAQ, valued at approximately $152,702.73. These shares were originally acquired as founder's compensation in 2021. The filing also details numerous …
An insider at Recursion Pharmaceuticals (RXRX) has filed a Form 144 notice to sell 100,000 Class A shares with an aggregate market value of over $304,000. These shares are identified as Founders Shares issued as compensation in 2021. The filing also reveals numerous large …
An insider associated with Recursion Pharmaceuticals, Inc. (RXRX) has filed a Form 144 to sell 100,000 Class A shares, valued at $289,766.37, through Fidelity Brokerage Services on July 20, 2026. These are documented as founder shares acquired as compensation on April 20, 2021. The …
In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.87% at $2.89. This change lagged the S&P 500's daily loss of 0.19%. At the same time, the Dow lost 0.59%, and the tech-heavy Nasdaq lost 0.05%. Shares of the biotechnology company have depreciated …
Sharemaestro market context Price below Trend Line 52 weeks -45.5% · Next-week setup negative 28.8%Search by ticker symbol or company name and select a result to open its chart.